B. Riley initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $10 price target. The firm says its investment thesis centers ...

B. Riley initiates Foghorn Therapeutics at buy with $10 price target, citing promising development of SMARCA2 inhibitors for ...

Foghorn Therapeutics Inc. (FHTX) has been beaten down lately with too much selling pressure. While the stock has lost 23.1% ...

Fintel reports that on January 30, 2025, B. Riley Securities initiated coverage of Foghorn Therapeutics (NasdaqGM:FHTX) with ...

Foghorn Therapeutics (FHTX) has received a new Buy rating, initiated by B.Riley Financial analyst, Kalpit Patel.Invest with Confidence: Follow ...

Foghorn Therapeutics shares are trading lower by 20.2% during Monday's session. The company announced it will discontinue independent development of its FHD-286 program. Foghorn Therapeutics Inc ...

Foghorn Therapeutics on Monday said it is ending independent development of its FHD-286 drug candidate following disappointing results from an early-stage study. Foghorn said the objective ...

Foghorn Therapeutics Inc. (FHTX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

Fintel reports that on January 30, 2025, B. Riley Securities initiated coverage of Foghorn Therapeutics (NasdaqGM:FHTX) with a Buy recommendation. As of January 28, 2025, the average one-year ...